Cantor Fitzgerald Predicts NeuroPace FY2025 Earnings

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of NeuroPace in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will earn ($0.79) per share for the year. The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share.

Several other research firms also recently commented on NPCE. Wells Fargo & Company dropped their price objective on shares of NeuroPace from $15.00 to $13.00 and set an "overweight" rating on the stock in a report on Wednesday, November 13th. JPMorgan Chase & Co. raised their price objective on shares of NeuroPace from $9.00 to $14.00 and gave the stock an "overweight" rating in a report on Tuesday, December 17th. Finally, UBS Group began coverage on shares of NeuroPace in a report on Tuesday. They set a "buy" rating and a $17.00 target price on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $15.33.

NeuroPace Stock Performance

Shares of NPCE traded down $0.02 on Thursday, reaching $14.02. 186,304 shares of the company's stock traded hands, compared to its average volume of 138,021. NeuroPace has a 52-week low of $5.45 and a 52-week high of $18.15. The stock has a market cap of $418.47 million, a PE ratio of -14.02 and a beta of 2.02. The stock's 50 day simple moving average is $11.13 and its two-hundred day simple moving average is $8.52. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03.

NeuroPace (NASDAQ:NPCE - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The company had revenue of $21.06 million during the quarter, compared to the consensus estimate of $19.33 million. During the same quarter in the prior year, the company posted ($0.28) earnings per share.

Institutional Investors Weigh In On NeuroPace

Several institutional investors and hedge funds have recently modified their holdings of NPCE. Bank of New York Mellon Corp purchased a new position in shares of NeuroPace during the second quarter valued at about $257,000. Rhumbline Advisers purchased a new position in shares of NeuroPace during the 2nd quarter worth approximately $111,000. XTX Topco Ltd grew its holdings in shares of NeuroPace by 56.1% during the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company's stock worth $182,000 after acquiring an additional 8,643 shares during the period. Millennium Management LLC raised its position in shares of NeuroPace by 13.3% in the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company's stock worth $5,186,000 after acquiring an additional 80,324 shares in the last quarter. Finally, Financial Advocates Investment Management lifted its stake in shares of NeuroPace by 20.0% in the 3rd quarter. Financial Advocates Investment Management now owns 18,000 shares of the company's stock valued at $125,000 after purchasing an additional 3,000 shares during the period. 78.83% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at NeuroPace

In other NeuroPace news, major shareholder Ltd. Kck sold 223,991 shares of the business's stock in a transaction on Friday, October 25th. The shares were sold at an average price of $5.45, for a total transaction of $1,220,750.95. Following the transaction, the insider now directly owns 5,270,845 shares of the company's stock, valued at approximately $28,726,105.25. The trade was a 4.08 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.20% of the stock is owned by company insiders.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.